Efficacy and Safety of Huanjingjian Decoction in Women With Premature Ovarian Insufficiency

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-39
SponsorShanghai Pulmonary Hospital, Shanghai, China

About this trial

Study Summary

This clinical trial aims to evaluate the efficacy and safety of the traditional Chinese herbal formula Huanjingjian decoction in women with premature ovarian insufficiency (POI). The study is designed to address the following key questions:

1. Does Huanjingjian decoction improve clinical symptoms in patients with POI? 2. What adverse medical events, if any, occur during the treatment with Huanjingjian decoction? To answer these questions, researchers will compare Huanjingjian decoction plus hormone replacement therapy (HRT) with placebo plus HRT, in order to determine whether Huanjingjian decoction provides additional therapeutic benefits in the management of POI.

Participants will:

Receiving either Huanjingjian decoction plus HRT, or placebo plus HRT. Attending monthly clinic visits over a 6-month period for clinical assessments and laboratory testing.

Keeping a detailed diary to record symptoms, treatment adherence, and menstrual flow, as measured by the number of sanitary pads used.

Eligibility criteria

Qualifiers

Age between 18 and 39 years

Meet the diagnostic criteria for Premature Ovarian Insufficiency (POI) according to the 2024 ESHRE Guideline on Premature Ovarian Insufficiency

Disqualifiers

Menstrual disorders attributable to congenital gonadal dysgenesis or acquired structural pathologies;

Menstrual irregularities secondary to endocrine disorders, including polycystic ovary syndrome (PCOS), hyperprolactinemia, dysfunctional uterine bleeding (DUB), gonadal hormone deficiency, hyperthyroidism, and other related endocrine conditions;

Oligomenorrhea or amenorrhea induced by surgical or medical interventions, such as chemotherapy, pelvic radiotherapy, ovarian cystectomy, ovarian drilling, ovarian wedge resection, salpingectomy, tubal ligation, pelvic abscess surgery, or uterine artery embolization;

History of abnormal vaginal bleeding accompanied by clinically significant findings on endometrial biopsy, or unexplained irregular vaginal bleeding within the preceding 12 months;

Trial design

Treatments tested in this trial

  • Huanjingjian decoction
  • Hormone replacement therapy
  • Placebo

Treatment groups

276 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Shanghai Pulmonary Hospital, Shanghai, China

Lead sponsor

Shanghai University of Traditional Chinese Medicine

Collaborator

Shanghai Geriatric Institute of Chinese Medicine

Collaborator

Shanghai Institute of Acupuncture and Anesthesia, Shanghai

Collaborator

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Collaborator

Jingan Hospital of Traditional Chinese Medicine

Collaborator